Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Suspicious citation numbers found in high-impact journals
The likely manipulation of citation numbers by research paper mills in high-impact cancer...
TGA developing reforms to strengthen sunscreen regulation
Brands would be required to test the SPF of their finished product, rather than just the base...
2026 Nobel Prize winners announced
It's that time of year again — the first of the 2026 Nobel Prizes have been announced.
